Orion (OEC)

NYSE Markt open

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

7.12 USD
−0.16 (-2.13%)

Laatst bijgewerkt

Marktkapitalisatie
410.51M
K/W
K/VKF
11.7
K/Omzet
0.23
Enterprise value
1.37B
Bedrijfssector
Bedrijfstak
Adres
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23 apr 2026, 11:00 A.M.
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24 feb 2026, 14:00 P.M.
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28 okt 2025, 11:00 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28 okt 2025, 11:00 A.M.
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18 jul 2025, 11:00 A.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09 jul 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17 jun 2025, 08:00 A.M.
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17 jun 2025, 08:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21 mei 2025, 06:30 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23 apr 2025, 11:00 A.M.
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21 mrt 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07 jan 2025, 08:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07 jan 2025, 08:00 A.M.
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18 dec 2024, 16:00 P.M.
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18 dec 2024, 16:00 P.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24 okt 2024, 18:50 P.M.
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24 okt 2024, 18:50 P.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14 okt 2024, 10:00 A.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14 okt 2024, 10:00 A.M.
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16 sep 2024, 10:30 A.M.
Marktkapitalisatie
410.51M
Enterprise value
1.37B
K/W
K/Boek
1.08
K/Omzet
0.23
Ondernemingswaarde / EBITDA
6.49
EV / Omzet
0.77
Winst per aandeel
-1.58
Dividendrendement
1.14%
K/VKF
11.7
K/KF
2.02
Vrije kasstroom
35.1M
Rendement op eigen vermogen
-23.48%
Rendement op activa
-4.61%
Schuld / Eigen vermogen
2.67
Current ratio
1
Quick ratio
0.62
Kas
0.08
Gem. volume
460.37K
Fundamentele snapshotprijs
7.28

Winst- en verliesrekening

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Omzet 459.5M 411.7M 450.9M 466.4M 477.7M
Brutowinst 79.2M 77.7M 85.6M 98.4M 98.1M
Operationele winst 11.4M 13.5M -52.3M 32.1M 31.2M
Resultaat vóór rente, belastingen en afschrijvingen 44.1M 41.3M 62.2M 64.1M 62.7M
Nettowinst -9.9M -21.1M -67.1M 9M 9.1M
Basis EPS -0.18 -0.37 -1.2 0.16 0.16
Verwaterde EPS -0.18 -0.37 -1.2 0.16 0.16

Balans

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Totaal activa 1.93B 1.91B 1.96B 2.02B 1.97B
Totaal passiva 1.55B 1.52B 1.56B 1.56B 1.5B
Totaal eigen vermogen 379.5M 384.6M 401.8M 466.5M 466.1M
Kas en equivalenten 50.5M 60.7M 51.3M 42.6M 37.5M
Vlottende activa 661.5M 643.8M 683.5M 682.5M 688.6M
Kortlopende passiva 659.7M 626.4M 635.3M 620.8M 601.9M

Kasstroom

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operationele kasstroom -12.4M 92.9M 68.8M 53.7M 400K
Investeringskasstroom -36.1M -48.7M -40.9M -42.2M -29.2M
Financieringskasstroom 39.6M -35.7M -19.5M -7.8M 21.8M
Mutatie kas -8.9M 8.5M 8.4M 3.7M -7M
Soort Deponering Datum Koppeling
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index 10-Q — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
form 4 Form 4 — Niewiem Sandra Deponering bekijken
form 4 Form 4 — Painter Corning F. Deponering bekijken
form 4 Form 4 — Puckett Jonathan A. Deponering bekijken
form 4 Form 4 — Quinones Carlos Deponering bekijken
form 4 Form 4 — Riveros Pedro Deponering bekijken
edgar index ARS — Orion S.A. Deponering bekijken
edgar index DEF 14A — Orion S.A. Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index PRE 14A — Orion S.A. Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index SCHEDULE 13G — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
form 4 Form 4 — Niewiem Sandra Deponering bekijken
form 4 Form 4 — Niewiem Sandra Deponering bekijken
form 4 Form 4 — Niewiem Sandra Deponering bekijken
form 4 Form 4 — Painter Corning F. Deponering bekijken
form 4 Form 4 — Painter Corning F. Deponering bekijken
form 4 Form 4 — Painter Corning F. Deponering bekijken
form 4 Form 4 — Quinones Carlos Deponering bekijken
form 4 Form 4 — Quinones Carlos Deponering bekijken
form 4 Form 4 — Quinones Carlos Deponering bekijken
form 4 Form 4 — Riveros Pedro Deponering bekijken
form 4 Form 4 — Riveros Pedro Deponering bekijken
form 4 Form 4 — Riveros Pedro Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index 10-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
ten k section 10-K — business Deponering bekijken
ten k section 10-K — mda Deponering bekijken
ten k section 10-K — risk_factors Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
form 4 Form 4 — Puckett Jonathan A. Deponering bekijken
edgar index 3 — Orion S.A. Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index 10-Q — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
eight k text 8-K — 8-K Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index 10-Q — Orion S.A. Deponering bekijken
edgar index SCHEDULE 13G/A — Orion S.A. Deponering bekijken
edgar index 8-K — Orion S.A. Deponering bekijken
edgar index SCHEDULE 13G/A — Orion S.A. Deponering bekijken
edgar index 3 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
edgar index 4 — Orion S.A. Deponering bekijken
form 4 Form 4 — GALVIN KERRY A Deponering bekijken